Business News

CytoSorbents Wins Contract

cropped-stockmarket01.jpg

CytoSorbents, a provider of critical care immunotherapy, said pre-market Monday that it won a two-year $999,996 “small business innovation research” (SBIR) phase II contract to continue development of CytoSorb for fungal mycotoxin blood purification.

This follows the successful completion of its previously announced $150,000 Phase I SBIR contract for mycotoxin removal. This contract is funded through the Chemical and Biological Defense (CBD) SBIR Program which represents a component of the Joint Chemical and Biological Defense Science & Technology Program.

By